Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Ranbaxy Case: Singh...

    Ranbaxy Case: Singh Brothers diverted funds despite SC orders, alleges Daiichi

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-04-12T14:30:33+05:30  |  Updated On 16 Aug 2021 4:37 PM IST



    "Their nearly Rs 6,300 crore has been syphoned off by some 'baba'. These children have been duped," Kapil Sibal had said, adding that let the properties of the contemnor be sold under the instruction of the court.


    New Delhi: Japanese firm Daiichi Sankyo told the Supreme Court Thursday that former Ranbaxy promoters, Malvinder and Shivinder Singh who owe it Rs 4,000 crore, have diverted funds despite several orders asking them to maintain their stakes in Fortis Healthcare Ltd. A bench comprising Chief Justice Ranjan Gogoi and Justices Deepak Gupta and Sanjiv Khanna reserved order on Daiichi's contempt plea against the former Ranbaxy promoters and others.


    Senior advocate F S Nariman, appearing for Daiichi, alleged that the Singh brothers diverted funds despite several orders by the Supreme Court to maintain their stake in Fortis Healthcare Ltd.


    Read Also: Supreme Court to directly hear contempt petition-Jail Singh Brothers if found guilty of non payment


    He said that they reduced their stakes in Fortis Healthcare Holding from more than 40 per cent on August 11, 2017, to less than 1 per cent now.


    The apex court had earlier expressed displeasure at the replies of Malvinder and Shivinder to its directive to submit a plan for paying Rs 4,000 crore to Daiichi Sankyo, as awarded by a Singapore tribunal.


    It had threatened to send them to jail if found that they have violated the apex court's order.


    Read Also: Singh Brothers booked under IPC 420 for Rs 2397 crore fraud


    On March 14, the Supreme Court asked them to submit a concrete plan for paying Rs 4,000 crore to Daiichi Sankyo as directed by a Singapore tribunal and had asked them to consult their accountants as also financial and legal advisors and appraise it by today.


    The bench considered the submissions of the lawyers representing Malvinder and Shivinder on their plans to give money for honouring the arbitral award.


    Read Also: Singh Brothers booked under IPC 420 for Rs 2397 crore fraud


    "Their nearly Rs 6,300 crore has been syphoned off by some 'baba'. These children have been duped," Kapil Sibal had said, adding that let the properties of the contemnor be sold under the instruction of the court.


    The Japanese firm has filed a contempt plea against the Singh brothers, saying that it was promised some shares of Fortis Healthcare by them and sought the recovery of Rs 3,500 crore as directed by the tribunal.


    The top court, on December 14 last year, had ordered status quo with regard to the sale of controlling stakes of Fortis Healthcare.


    Read Also: How will you pay Rs 3500 crore arbitral award to Daiichi: Supreme Court asks Singh Brothers


    The board of Fortis Healthcare had approved in July a proposal from IHH Healthcare to invest Rs 4,000 crore by way of preferential allotment for a 31.1 per cent stake.


    The Malaysian IHH Healthcare Bhd became the controlling shareholder of Fortis Healthcare Ltd by acquiring a 31.1 per cent stake in the company.


    Daiichi had bought Ranbaxy in 2008. Later, it had moved the Singapore arbitration tribunal alleging that the Singh brothers had concealed information that Ranbaxy was facing a probe by the US Food and Drug Administration and the Department of Justice while selling its shares.


    Read Also: Fortis Healthcare petitions SEBI seeking arrest of Singh brothers


    Daiichi had to enter into a settlement agreement with the US Department of Justice, agreeing to pay USD 500 million penalties to resolve potential, civil and criminal liability.


    The company had then sold its stake in Ranbaxy to Sun Pharmaceuticals for Rs 22,679 crore in 2015.





    Chief Justice Ranjan GogoiDaiichi SankyoEX RanbaxyFHLFortisFortis HealthcareIHH HealthcareJustice Deepak GuptaJustice Sanjiv KhannaMalvinderpharmapharmacyRanbaxyranbaxy promotersShivinder SinghSingapore tribunalSingh brothersSun PharmaceuticalsSupreme Court
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok